NDA 214517 · Vanda Pharms INC
Hetlioz Lq
Tasimelteon · Oral · Melatonin Receptor Agonist
Priority reviewOrphanLast checked: Nov 19, 2026Latest source record: Dec 1, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Dec 1, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
25
12 Phase 3, 2 recruiting
FAERS reports
5,893
601 serious, 166 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 4, 2026.
HETLIOZ is a melatonin receptor agonist. HETLIOZ capsules are indicated for the treatment of: Non-24-Hour Sleep-Wake Disorder (Non-24) in adults ( 1 ) Nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in patients 16 years of age and older ( 1 ) HETLIOZ LQ oral suspension is indicated for the treatment of: Nighttime sleep disturbances in SMS in pediatric patients 3 years to 15 years of age ( 1 ) 1.1 Non-24-Hour Sleep-Wake Disorder (Non-24) HETLIOZ capsules are indicated for the treatment of Non-24 in adults. 1.2 Nighttime Sleep Disturbances in Smith-Magenis Syndrome (SMS) HETLIOZ capsules are indicated for the treatment of nighttime sleep disturbances in SMS in patients 16 years of age and older. HETLIOZ LQ oral suspension is indicated for the treatment of nighttime sleep disturbances in SMS in pediatric patients 3 to 15 years of age.
Mechanism: The mechanism by which tasimelteon exerts its therapeutic effect in patients with Non-24 or nighttime sleep disturbances in SMS is unclear. However, tasimelteon is an agonist at melatonin MT 1 and MT 2 receptors which are thought to be involved in the control of circadian rhythms.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- HETLIOZ LQ · TASIMELTEON 4MG/ML · SUSPENSION, ORAL · Prescription
- HETLIOZ LQ · TASIMELTEON 4MG/ML · SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tasimelteon" as an intervention, any sponsor and status, largest first.
- Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive DisorderPivotal-lookingCompleted
Vanda PharmaceuticalsIndustry
NCT01428661 · 507 participants · Start Sep 2011 · Primary completion Jan 2013
Drug: tasimelteon; placebo · For: Major Depressive Disorder
Sites: Garden Grove, California; Irvine, California; Los Alamitos, California · 40 sites in all
- Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric InsomniaPivotal-lookingRecruiting
Vanda PharmaceuticalsIndustry
NCT06953869 · 420 participants (planned) · Start Apr 21, 2025 · Primary completion Nov 2027
Drug: Tasimelteon Oral Suspension; Placebo · For: Insomnia Disorder
Sites: Dothan, Alabama; Phoenix, Arizona; Irvine, California · 35 sites in all
- VEC-162 Study in Adult Patients With Primary InsomniaPivotal-lookingCompleted
Vanda PharmaceuticalsIndustry
NCT00548340 · 322 participants · Start Nov 2007 · Primary completion Feb 2008
Drug: VEC-162 20 mg; Placebo and 1 more · For: Primary Insomnia
Sites: Birmingham, Alabama; Hot Springs, Arkansas; Little Rock, Arkansas · 35 sites in all
- Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type InsomniaPivotal-lookingCompleted
Vanda PharmaceuticalsIndustry
NCT03373201 · 320 participants · Start Oct 16, 2017 · Primary completion Mar 5, 2018
Drug: Tasimelteon; Placebo · For: Jet Lag Type Insomnia
Sites: Little Rock, Arkansas; Alameda, California; San Diego, California · 12 sites in all
- Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light PerceptionPivotal-lookingCompleted
Vanda PharmaceuticalsIndustry
NCT01429116 · 200 participants (planned) · Start Oct 2011 · Primary completion Jan 2015
Drug: tasimelteon · For: Non-24-Hour Sleep-Wake Disorder
Sites: Phoenix, Arizona; Orange, California; Palo Alto, California · 22 sites in all
- Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light PerceptionPivotal-lookingStatus unknown
Vanda PharmaceuticalsIndustry
NCT01218789 · 140 participants (planned) · Start Oct 28, 2010 · Primary completion Dec 5, 2024
Drug: tasimelteon · For: Non 24 Hour Sleep Wake Disorder
Sites: Garches, France; Lille, France; Lyon, France · 7 sites in all
- Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake DisorderPivotal-lookingCompleted
Vanda PharmaceuticalsIndustry
NCT01163032 · 136 participants · Start Aug 2010 · Primary completion Nov 2012
Drug: tasimelteon; Placebo · For: Non-24-Hour Sleep-Wake Disorder
Sites: Phoenix, Arizona; Orange, California; Palo Alto, California · 28 sites in all
- Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep DisturbancesPivotal-lookingStatus unknown
Vanda PharmaceuticalsIndustry
NCT05361707 · 100 participants (planned) · Start Jul 28, 2021 · Primary completion Jul 2025
Drug: Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension · For: Autism Spectrum Disorder; Sleep Disorder; Neurological Disorder and 1 more
Sites: San Jose, California; San Leandro, California; Santa Monica, California · 5 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,652
- insomnia747
- product dose omission issue504
- middle insomnia424
- somnolence412
- headache387
- nightmare272
- fatigue225
- abnormal dreams224
- therapeutic product effect decreased199
- sleep disorder193
- inappropriate schedule of product administration185
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 9 |
| 2015 | 577 |
| 2016 | 408 |
| 2017 | 308 |
| 2018 | 540 |
| 2019 | 776 |
| 2020 | 741 |
| 2021 | 731 |
| 2022 | 556 |
| 2023 | 562 |
| 2024 | 377 |
| 2025 | 177 |
| 2026 | 131 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Hetlioz Lq (Tasimelteon)
2024 spending
$1.3M
Beneficiaries
n/a
60 claims
Per beneficiary
n/a
$152.06 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $436,703 |
| 2023 | $843,053 |
| 2024 | $1,330,485 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Absolute Bioavailability of Tasimelteon.
Torres R, Dressman MA, Kramer WG, et al. · Am J Ther 2015 · Randomized Controlled Trial
- Simulated driving performance in healthy adults after night-time administration of 20 mg tasimelteon.
Torres R, Fisher M, Birznieks G, et al. · J Sleep Res 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial.
Synnott NC, Polymeropoulos CM, Xiao C, et al. · PLoS One 2025 · Randomized Controlled Trial, Multicenter Study
- Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.
Rajaratnam SM, Polymeropoulos MH, Fisher DM, et al. · Lancet 2009 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies.
Leger D, Quera-Salva MA, Vecchierini MF, et al. · Expert Opin Drug Saf 2015 · Meta-Analysis
- Tasimelteon safely and effectively improves sleep in Smith-Magenis syndrome: a double-blind randomized trial followed by an open-label extension.
Polymeropoulos CM, Brooks J, Czeisler EL, et al. · Genet Med 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Vanda Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.